Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus
Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus
Although generalized convulsive status epilepticus (GCSE) is a life-threatening emergency,
 evidence-based data to guide initial drug treatment choices are lacking in the Chinese
 population. The investigators conduct this prospective randomized controlled trial to
 evaluate the relative efficacy and safety of intravenous (IV) phenobarbital (PB) and
 valproate (VPA) in patients with GCSE.
After the failure of first-line diazepam treatment, patients with GCSE are randomized to
 receive either IV PB (standard doses, low rate) or VPA (standard). Successful treatment is
 considered when clinical and electroencephalographic seizure activity ceases. Adverse events
 following treatment and the neurological outcomes at discharge and 3 months later are also
 evaluated.
Inclusion Criteria:

 -  All consecutive GCSE patients (after the failure of first-line diazepam treatment) who
 were admitted in the emergency room or neurocritical care unit in Xuanwu Hospital of
 Capital Medical University.

 Exclusion Criteria:

 -  Unstable vital signs, such as a systolic blood pressure of <90 mm Hg, a pulse of <60
 beats per min, or an arterial blood oxygen saturation of <90%,

 -  Liver dysfunction (alanine transaminase or total bilirubin of more than twice the
 normal upper limit),

 -  Neurologic emergency requiring immediate surgical intervention,

 -  Pregnancy or breast feeding,

 -  Hypersensitivity to study drugs.